Pacira BioSciences Inc (PCRX) concluded trading on Thursday at a closing price of $24.65, with 0.45 million shares of worth about $11.06 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 47.69% during that period and on April 17, 2025 the price saw a gain of about 0.74%. Currently the company’s common shares owned by public are about 46.24M shares, out of which, 44.24M shares are available for trading.
Stock saw a price change of 4.05% in past 5 days and over the past one month there was a price change of 1.52%. Year-to-date (YTD), PCRX shares are showing a performance of 30.84% which decreased to -8.26% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $11.16 but also hit the highest price of $31.67 during that period. The average intraday trading volume for Pacira BioSciences Inc shares is 935.49K. The stock is currently trading 0.29% above its 20-day simple moving average (SMA20), while that difference is up 0.10% for SMA50 and it goes to 24.99% higher than SMA200.
Pacira BioSciences Inc (NASDAQ: PCRX) currently have 46.24M outstanding shares and institutions hold larger chunk of about 111.47% of that.
The stock has a current market capitalization of $1.14B and its 3Y-monthly beta is at 0.56. It has posted earnings per share of -$2.20 in the same period. It has Quick Ratio of 2.00 while making debt-to-equity ratio of 0.82. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for PCRX, volatility over the week remained 3.66% while standing at 5.54% over the month.
Stock’s fiscal year EPS is expected to drop by -9.37% while it is estimated to increase by 25.68% in next year. EPS is likely to grow at an annualized rate of 12.47% for next 5-years, compared to annual growth of -51.99% made by the stock over the past 5-years.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Truist on January 30, 2025 offering a Hold rating for the stock and assigned a target price range of between $8 and $25 to it. Coverage by Truist stated Pacira BioSciences Inc (PCRX) stock as a Sell in their note to investors on August 13, 2024, suggesting a price target of $8 for the stock. Stock get a Neutral rating from Piper Sandler on August 12, 2024.
